Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for MDD and Alcohol Use Disorder
NCT04620759Phase 2Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Apr 2021
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), alcohol use disorder (AUD), sponsored by Johns Hopkins University. Started Apr 2021; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT04620759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620759.